Surgery, Sedation and a Stomach That Empties Slowly: What the GLP-1 Labels Actually Say

Answer first: one instruction, and one admission

Every one of these five labels carries a Warnings and Precautions section called Pulmonary Aspiration During General Anesthesia or Deep Sedation. The paragraph under it is word-for-word identical across all five documents, with nothing changed but the brand name.

It contains exactly one instruction to patients: tell your healthcare providers before any planned surgery or procedure that you are taking this drug.

It also contains something rarer than an instruction, which is an admission. Available data are insufficient to inform recommendations to mitigate the risk, the labels say, including whether modifying preoperative fasting recommendations or temporarily discontinuing the drug could reduce the incidence of retained gastric contents.

Read that carefully, because it is the whole point of the page. The labels raise a risk, describe the mechanism, and then decline to say whether the obvious countermeasures — fasting longer, or pausing the drug — actually work. They are not being coy. They are saying the evidence to answer that question does not exist yet.

What the warning describes

The mechanism is stated in the first line of each paragraph: the drug delays gastric emptying, with a cross-reference to the pharmacodynamics section.

The concern that follows is specific and physical. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, who had residual gastric contents despite reported adherence to preoperative fasting recommendations.

Two qualifiers in that sentence carry most of its weight. The reports are described as rare. And they involve people who, by their own account, had followed the fasting instructions they were given.

That second detail is the reason the warning exists at all. Preoperative fasting rules assume a stomach that empties on a roughly predictable schedule. A drug that slows emptying is a reason to question that assumption, and the postmarketing reports are what prompted someone to write it down.

The word postmarketing matters too. These are reports gathered after approval, from ordinary use, rather than events counted in a controlled trial. That is a real signal and a weak kind of evidence at the same time, which is exactly why the paragraph that follows says what it says.

The sentence where the labels decline to advise

Here is the load-bearing sentence, in the form all five labels print it: available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking the drug, including whether modifying preoperative fasting recommendations or temporarily discontinuing the drug could reduce the incidence of retained gastric contents.

Both candidate countermeasures are named, and both are left unresolved. Fasting longer is not endorsed. Pausing the medication is not endorsed. Neither is ruled out either.

This is unusual and it is honest. A label is allowed to stay silent on a question it cannot answer; choosing instead to name the two things everyone would guess at, and to say the data cannot support either, is a deliberate act of scope-setting.

It also means that anyone who tells you confidently what the label says to do before surgery is describing something the label does not contain. Institutions and professional societies issue their own procedural guidance, and an anesthesiology team works from that and from your individual case. That guidance is a different document with a different evidence standard, and it is not what these five labels say.

The practical consequence for a patient is narrow and clear. The decision belongs to the people running your procedure, and they can only make it if they know you are on the drug.

The one thing the labels do instruct

The instruction is the last line of the same paragraph and the same line appears again in the patient counseling section of every label: instruct patients to inform healthcare providers prior to any planned surgeries or procedures that they are taking the drug.

The counseling section adds the plain-language version, and it is worth having the phrasing because it is the sentence a patient is meant to hear: this drug may cause your stomach to empty more slowly, which may lead to complications with anesthesia or deep sedation during planned surgeries or procedures.

Note the breadth of planned surgeries or procedures. The warning is not confined to major operations. Deep sedation is named alongside general anesthesia, which brings in a range of routine procedures that people do not always think of as surgery.

Note also who is being told. Healthcare providers, plural, before the procedure. The prescriber who writes for a GLP-1 and the team performing a procedure are frequently different practices with no shared record, and a telehealth program adds a third party that may be invisible to both.

This is a low-effort, high-value disclosure. It costs one sentence at a pre-procedure appointment, and it is the only action item the label actually asks of a patient.

Severe gastroparesis: the other stomach-emptying line

There is a second sentence about the stomach on all five labels, in a different section, and it is easy to miss because it sits at the end of a paragraph about gastrointestinal side effects.

Each label states that the drug is not recommended in patients with severe gastroparesis. That sentence appears verbatim on all five, with only the brand name differing.

Gastroparesis is delayed gastric emptying as a diagnosed condition rather than as a drug effect. The reasoning is not spelled out on the label, but the shape of it is not hard to see: a drug whose known action is to slow the stomach is a poor fit for a stomach that is already too slow.

Not recommended is weaker language than contraindicated, and the difference is deliberate. The thyroid contraindication is a rule. This is a judgment the label hands to the prescriber.

It is still a question worth surfacing, because gastroparesis often travels with long-standing diabetes, which is precisely the population two of these labels are written for. If you have been told your stomach empties slowly, that is a thing to say out loud during an intake rather than to wait to be asked about.

Why an identical paragraph on five labels is itself informative

It is worth pausing on the fact that this text is the same on all five documents when almost nothing else on them is.

Compare it with the gallbladder warning, which sits a few sections away. There, each of the five labels reports its own trial numbers, its own comparison against placebo, and its own conclusion about whether weight loss explains the finding. Those five paragraphs differ substantially from one another.

The aspiration paragraph does not vary at all. That pattern is what a class-wide safety labeling change looks like from the outside: identical language applied across a drug class based on shared postmarketing evidence, rather than each manufacturer writing up its own trial.

For a reader, this has a practical implication that is easy to state. On this particular question, there is no better or safer molecule in the group to switch to. The warning does not distinguish between them, and neither does the evidence behind it.

It also means the answer will not change by shopping around. Any product in this class, from any prescriber, carries the same paragraph and the same unresolved question.

What to say, and to whom

Tell the team running any procedure that you take a GLP-1, and name the molecule generically rather than by a program's brand. That is the label's only instruction and it is the one that reliably gets missed.

Say it early enough to matter. Pre-procedure calls and anesthesia consults happen days ahead precisely so that this kind of information can change a plan, and a disclosure at check-in is a harder problem than the same disclosure a week earlier.

Include dental work, endoscopy, and anything described as involving sedation. The label names deep sedation alongside general anesthesia, and procedures that are routine are still procedures.

Do not decide on your own to pause or continue anything ahead of a procedure. The labels specifically say the data cannot tell you whether pausing helps, which means that choice is a clinical judgment about your case rather than a rule you can look up. Ask the team who will be sedating you.

And if you have been diagnosed with gastroparesis, raise it before anything is prescribed. All five labels say these drugs are not recommended in severe cases, and that is a conversation to have at the start rather than after.